Canada: Federal Court Of Appeal Finds Sanofi’s Plavix Patent Valid And Infringed

Last Updated: August 2 2013
Article by Andrea Berenbaum and Patricia Folkins

In Sanofi-Aventis v Apotex Inc, the Federal Court of Appeal1 (FCA) concluded that the Federal Court erred in its judgment (reported here), that Sanofi's Canadian Patent No. 1,336,777 (the '777 Patent) was invalid and consequently allowed Sanofi's action for infringement. This decision is of particular interest for its comments on the promise of the patent, an important but controversial aspect of the utility analysis in Canada.


The '777 Patent is a selection patent. It relates to the active and less toxic enantiomer of a racemate2 known as PCR 4099 which falls within a large genus of racemates claimed in Sanofi's Canadian Patent No. 1,194,875 (the '875 Patent). The bisulfate salt of the enantiomer of the '777 Patent is the active ingredient in the anticoagulant drug PlavixTM.

Apotex had previously sought marketing authorization from Health Canada for a generic version of clopidogrel. Sanofi responded by bringing an application under the Patented Medicines (Notice of Compliance) Regulations, a case which ultimately ended up before the Supreme Court of Canada (SCC). In Apotex Inc v Sanofi-Synthelabo Canada Inc ("Plavix"), the SCC found that Apotex's allegations that the '777 Patent was invalid for anticipation, obviousness and double patenting were not justified.

Apotex subsequently commenced an action in the Federal Court seeking a declaration that the '777 Patent was invalid3. The Federal Court found that the '777 Patent was invalid because the utility of the invention had neither been demonstrated nor soundly predicted as of the filing date of the patent application. A determinative factor in the utility analysis was the Federal Court's conclusion that the '777 Patent promises the use of the invention in humans. This conclusion was reached using inferences based on the wording of the '777 Patent as well as the fact that the genus '875 Patent explicitly mentions use in humans. The Federal Court further went on to consider obviousness, and also found the '777 Patent invalid on this ground.

The FCA Decision

The Canadian courts, including the Federal Court in the present case, have been citing a passage from the FCA decision in Olanzapine for the role of the promise of the patent in a utility analysis. This passage provides that where the patent specification does not promise a specific result, no particular level of utility is required and a mere scintilla of utility will suffice but where the specification sets out an explicit promise, utility will be measured against that promise and the question is whether the invention does what the patent promises it will do. In the present case, the FCA clarified that not every patent contains an explicit promise of a specific result as there is generally no obligation on an inventor to disclose the utility of an invention in a patent. On the other hand, selection patents such as the '777 Patent must set out an explicit promise because of the requirement that both the novelty of the selection and its utility (the advantage secured or the disadvantage avoided by the selection) must be described in the patent.

This decision appears to hold that the mere scintilla standard should be applied unless a skilled person would understand the specification to contain an explicit promise of a specific result. While an inventor who promises more for his invention than required can render his patent invalid by a self-inflicted wound, here the FCA held that the Federal Court erred "in reading into the '777 Patent a promise for use in humans on the basis of inferences, in the absence of language at least as clear and unambiguous as that used to establish the advantages of the selection over the compounds of the genus patent."

The FCA also held that the Federal Court erred in holding that, because the '875 Patent contained a reference to use in humans, the '777 Patent would fail as a selection patent unless an explicit promise for use in humans was also read into it. First, the FCA affirmed a long line of case law holding that is improper to construe a patent with an eye to its validity. Further, the FCA held that it is sufficient that the unexpected advantage of a selection patent is a new and useful improvement on some aspect of the invention described in the genus patent; it need not be an improvement on every aspect.

With respect to obviousness, the FCA held that the Federal Court again erred in holding that the invention was obvious based on the fact that the resolution of the racemate PCR 4099 was obvious to try. It held that the focus of the obviousness analysis in Plavix was not the difficulty in separating the racemates covered by the '875 Patent but rather the unknown properties of the resulting enantiomers, and it was the lack of knowledge as to these properties that led the SCC to hold that it was not self-evident that what was being tried ought to work. As the results to be obtained were unknown, the FCA held that the distance between the common general knowledge and the inventive concept of the '777 Patent could not be bridged by routine experimentation.

Summary and Outlook

In the present case, the FCA stressed that Courts should not strive to find ways to defeat otherwise valid patents. While this suggests that the Canadian courts may be less motivated to read an explicit promise into a patent based on inferences, it remains important (as noted here) to consider the language used in an application to describe a promised utility to ensure it does not elevate the utility beyond that which is supported. The decision also confirms that selection patents must disclose the advantage secured or disadvantage avoided by the selection but clarifies that it is sufficient that this be a new and useful improvement on some aspect of the invention described in the genus patent; not every aspect. Apotex may still seek leave to appeal this decision to the SCC.


1 Reasons for judgment were provided by Pelletier JA, concurred in by Noël JA. Gauthier JA agreed that the appeal should be allowed for the reasons given by Pelletier JA but in concurring reasons commented further on certain issues in respect of utility and obviousness.

2 A racemate is a mixture of equal amounts of two compounds known as enantiomers which differ in structure in that they are mirror images of each other.

3 Sanofi also brought an action alleging Apotex infringed this patent. The two actions were consolidated, and the Federal Court held that the '777 Patent would have been infringed if it were not invalid.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Andrea Berenbaum
Patricia Folkins
Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions